Search clinical trials for: VBI-2901e

Total 2505 results

University Hospital, Basel, Switzerland

Completed

Oral Vitamin D Substitution Weekly or Monthly and Adherence

Vitamin D Deficiency

Switzerland
University of Nebraska
National Cancer Institute (NCI)

Terminated

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of of Olodaterol and Ketoconazole

Healthy | Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood

Healthy

Germany
AbbVie

Completed

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Brazil
VIVUS LLC

Completed

A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

Adolescent Obesity | Obesity in Adolescence | Adolescent Overweight

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
Boehringer Ingelheim

Completed

Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers

Healthy

Germany
Sun Yat-sen University

Recruiting

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

Hepatocellular Carcinoma Recurrent

China
GlaxoSmithKline

Completed

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany, Spain, United States, United Kingdom
Boehringer Ingelheim

Completed

Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

Healthy

Germany
Novartis Vaccines

Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Meningococcal Disease | Meningococcal Meningitis

Spain, Brazil, Hungary, Peru
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Healthy

Germany
Fred Hutchinson Cancer Center
Medexus Pharma, Inc.

Recruiting

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Celgene

Completed

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer (FABLOx)

Metastatic Pancreas Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Malignant Neoplasm

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of BI 1810631 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Boehringer Ingelheim

Completed

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Healthy
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Cancer

Canada, United States
Masonic Cancer Center, University of Minnesota

Completed

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | MDS | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Refractory Anemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Leukemia

United States
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Natural Killer Cell Lymphoblastic Leukemia/Lymphoma

United States, Australia, Canada
Masonic Cancer Center, University of Minnesota
National Marrow Donor Program

Completed

Stem Cell Transplant for Hemoglobinopathy

Sickle Cell Disease | Thalassemia | Severe Congenital Neutropenia | Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States, Germany, Italy
University of Washington
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
University of Chicago

Completed

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
M.D. Anderson Cancer Center

Completed

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma (BCAA)

Melanoma

United States
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Rabies Virus Infection

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7

United States
Shanghai Zhongshan Hospital

Completed

The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery

Lung Neoplasms | Esophageal Neoplasms | Venous Thromboembolism

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma

United States
University of Washington
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal...

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Glioma | Glioblastoma

United States
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers

Healthy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States

Search clinical trials for: VBI-2901e

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations